Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01297543 · ClinicalTrials.gov registry record · Phase 1

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia

A Phase 1 study of Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia, sponsored by Cellerant Therapeutics.

Completed
Registry status
Phase 1
Development phase
45
Enrollment target
10
Study locations

NCT01297543: Completed Phase 1 study of Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia, sponsored by Cellerant Therapeutics.

NCT01297543 is a Phase 1 study of Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia that has completed, run by Cellerant Therapeutics. The registered enrollment target is 45 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (61% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01297543, a Phase 1 study of Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia, has completed, sponsored by Cellerant Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
45 participants
Enrollment target
10
Study locations

Study Summary

Ex vivo expanded human myeloid progenitor cells (hMPCs; CLT-008) have the potential to accelerate neutrophil recovery and decrease the risk of febrile neutropenia and infection in patients receiving chemotherapy for acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), or high-risk myelodysplasia (MDS). In this study, the safety, tolerability and activity of CLT-008 administered after "standard of care" cytarabine-based consolidation or induction/re-induction chemotherapy will be determined by monitoring for adverse reactions, infusion reactions, graft-versus host disease (GVHD), neutrophil and platelet recovery, hMPC persistence, infections and complications.

Conditions Studied

Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Chronic Myeloid Leukemia Myelodysplasia

Interventions

  • DRUG G-CSF
  • BIOLOGICAL human myeloid progenitor cells

Study Locations (10)

California

  • Moores UCSD Cancer Center - La Jolla
  • University of California San Francisco Medical Center - San Francisco
  • Stanford Hospital and Clinics - Stanford

Illinois

  • Loyola University Medical Center, Cardinal Bernardin Cancer Center - Maywood

Indiana

  • Indiana Blood and Marrow Transplantation, LLC - Beech Grove

Massachusetts

  • University of Massachusetts Memorial Medical Center - Worcester

Minnesota

  • University of Minnesota - Minneapolis

Ohio

  • Cleveland Clinic - Cleveland

Pennsylvania

  • The Western Pennsylvania Hospital - Pittsburgh

Texas

  • The University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2011-03
Est. Completion 2015-01
Phase Phase 1
Cellerant Therapeutics

3 total trials

What the finished NCT01297543 record still lists

NCT01297543 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (61% lower).

The record links to 4 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 2 interventions - of which G-CSF is the first listed.

NCT01297543 lists 10 locations in 8 states (California, Illinois, Indiana).

Frequently Asked Questions

What is clinical trial NCT01297543 about?

NCT01297543 is a clinical study titled "Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia". Ex vivo expanded human myeloid progenitor cells (hMPCs; CLT-008) have the potential to accelerate neutrophil recovery and decrease the risk of febrile neutropenia and infection in patients receiving chemotherapy for acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid le...

What is the current status of trial NCT01297543?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2011-03. Estimated completion is 2015-01.

What conditions does trial NCT01297543 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Myelodysplasia.

What interventions are being tested in trial NCT01297543?

The interventions under investigation include: G-CSF (DRUG), human myeloid progenitor cells (BIOLOGICAL).

Who is sponsoring clinical trial NCT01297543?

This trial is sponsored by Cellerant Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01297543 being conducted?

This trial has 10 study locations across California, Illinois, Indiana, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01297543's enrollment target sits among peer trials

45 158th of 306 higher than 145 of 306 other Acute Myeloid Leukemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Acute Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00804154 · 45 participants · Phase 1

    Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

  • NCT01851694 · 45 participants · NA

    Beta-cell Response to Incretin Hormones in Cystic Fibrosis

  • NCT02896335 · 45 participants · Phase 2

    Palbociclib and Pembrolizumab In Central Nervous System Metastases

  • NCT03454035 · 45 participants · Phase 1

    Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01297543, the US trial registry maintained by the National Library of Medicine. NCT01297543 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.